Literature DB >> 9048374

An investigation of the physical characteristics of 66Ga as an isotope for PET imaging and quantification.

M C Graham1, K S Pentlow, O Mawlawi, R D Finn, F Daghighian, S M Larson.   

Abstract

Isotopes commonly used for PET imaging and quantification have a straightforward decay scheme involving "pure" positron (beta +) emission, i.e., 95%-100% beta + abundance, with no additional gamma rays. 66Ga (Emax = 4.2 MeV, T1/2 = 9.5 h) is a member of a category of isotopes with a lower abundance of beta +'s (57%) and a more complicated spectrum involving combinations of gamma rays that are emitted in cascade. These additional gamma rays tend to cause a higher singles rate, resulting in more random coincidence events. The most abundant positron (51.5%) in the spectrum has one of the highest energies considered for PET imaging. For the purpose of monoclonal antibody dosimetry using 66Ga, it is important to verify the quantification in phantoms prior to initiating human studies. A series of quantitative phantom measurements were performed on the PC4600, a head-optimized BGO based scanner with multiple detector rings. Count rate linearity was verified over concentrations ranging from 4.0 kBq/cc to 37 kBq/cc (0.11-1.0 microCi/cc); resolution averaged 16 mm full width half-maximum in the x and y directions in both the direct and cross planes. Axial resolution was 14 mm. The range of the energetic positrons (up to 4.153 MeV, range 7.6 mm in tissue) was verified as a primary source of resolution degradation. Within the limits outlined above, 66Ga is a suitable isotope for use as 66Ga citrate or with monoclonal antibodies in the detection and staging of tumors and other lesions. In addition, the energetic positrons have possible therapeutic applications when used as a monoclonal antibody label.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048374     DOI: 10.1118/1.597924

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene.

Authors:  Hao Hong; Yin Zhang; Jonathan W Engle; Tapas R Nayak; Charles P Theuer; Robert J Nickles; Todd E Barnhart; Weibo Cai
Journal:  Biomaterials       Date:  2012-03-03       Impact factor: 12.479

2.  Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.

Authors:  Jonathan W Engle; Hao Hong; Yin Zhang; Hector F Valdovinos; Duane V Myklejord; Todd E Barnhart; Charles P Theuer; Robert J Nickles; Weibo Cai
Journal:  Mol Pharm       Date:  2012-04-21       Impact factor: 4.939

Review 3.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

4.  Folate-based radiotracers for PET imaging--update and perspectives.

Authors:  Cristina Müller
Journal:  Molecules       Date:  2013-04-29       Impact factor: 4.411

5.  66Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?

Authors:  Alejandro Amor-Coarasa; James M Kelly; Shashikanth Ponnala; Anastasia Nikolopoulou; Clarence Williams; John W Babich
Journal:  Molecules       Date:  2018-10-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.